Comparison · NCT02363322-sae
B/Current Standard of Care Plus ZMapp vs A/Current Standard of Care Alone: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. B/Current Standard of Care Plus ZMapp vs A/Current Standard of Care Alone: serious adverse events. Trial comparisons, record NCT02363322-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02363322-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.306 | 0.18 | 0.469 | wilson | |
| Risk in group 2 | 0.371 | 0.232 | 0.537 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0659 | -0.273 | 0.149 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.823 | 0.428 | 1.58 | log | |
| Odds ratio, group 1 over group 2 | 0.745 | 0.278 | 2 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on B/Current Standard of Care Plus ZMapp than on A/Current Standard of Care Alone | 15.2 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: standard of care.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | B/Current Standard of Care Plus ZMapp | ZMapp (Trademark) + Optimized standard of care to include aggressive fluid resuscitation, hemodynamic support, and other interventions available in an optimized care setting.~ZMApp: Triple monoclonal cocktail of antibodies against Zaire species of Ebola virus | 11 | 36 | EG001 |
| Group 2 | A/Current Standard of Care Alone | Optimized standard of care to include aggressive fluid resuscitation, hemodynamic support, and other interventions available in an optimized care setting | 13 | 35 | EG000 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- 8 months, from March 2015 through November 2015
Source ClinicalTrials.gov
Trial
- Title
- Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola Infection
- NCT number
- NCT02363322
- Phases
- PHASE1, PHASE2
- Conditions
- Ebola Virus Infection
- Interventions
- B/Current Standard of Care Plus ZMapp, A/Current Standard of Care Alone
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Results first posted
- 2019-05-14
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02363322?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02363322-sae